170 related articles for article (PubMed ID: 15808815)
1. Gefitinib does not increase survival in lung cancer patients.
Golsteyn RM
Drug Discov Today; 2005 Mar; 10(6):381. PubMed ID: 15808815
[No Abstract] [Full Text] [Related]
2. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
Friedrich MJ
J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
[No Abstract] [Full Text] [Related]
3. Failing survival advantage in crucial trial, future of Iressa is in jeopardy.
Twombly R
J Natl Cancer Inst; 2005 Feb; 97(4):249-50. PubMed ID: 15713955
[No Abstract] [Full Text] [Related]
4. Gefitinib: phoenix from the flames.
Lancet Oncol; 2009 Aug; 10(8):737. PubMed ID: 19647191
[No Abstract] [Full Text] [Related]
5. Cancer drugs. Smart weapons prove tough to design.
Couzin J
Science; 2002 Oct; 298(5593):522-5. PubMed ID: 12386312
[No Abstract] [Full Text] [Related]
6. More haste, less speed.
Lancet Oncol; 2003 Jun; 4(6):325. PubMed ID: 12788389
[No Abstract] [Full Text] [Related]
7. Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
Belani CP; Ramalingam S
Clin Lung Cancer; 2005 Jan; 6(4):203-4. PubMed ID: 15694010
[No Abstract] [Full Text] [Related]
8. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
Morita S; Okamoto I; Kobayashi K; Yamazaki K; Asahina H; Inoue A; Hagiwara K; Sunaga N; Yanagitani N; Hida T; Yoshida K; Hirashima T; Yasumoto K; Sugio K; Mitsudomi T; Fukuoka M; Nukiwa T
Clin Cancer Res; 2009 Jul; 15(13):4493-8. PubMed ID: 19531624
[TBL] [Abstract][Full Text] [Related]
9. FDA Oncology Committee debates Iressa's status following negative trial results.
Twombly R
J Natl Cancer Inst; 2005 Apr; 97(7):473. PubMed ID: 15812066
[No Abstract] [Full Text] [Related]
10. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
Comis RL
Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
[No Abstract] [Full Text] [Related]
11. Gefitinib: new preparation. Non small-cell lung cancer: stricter assessment needed.
Prescrire Int; 2004 Oct; 13(73):168-70. PubMed ID: 15499696
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib. Still no convincing results in non-small cell lung cancer.
Prescrire Int; 2010 Jun; 19(107):113. PubMed ID: 20738034
[No Abstract] [Full Text] [Related]
13. Gefitinib for advanced or metastatic non-small cell lung cancer.
Perras C
Issues Emerg Health Technol; 2004 Apr; (55):1-4. PubMed ID: 15085875
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial of Iressa.
FDA Consum; 2005; 39(2):4. PubMed ID: 16121415
[No Abstract] [Full Text] [Related]
16. Iressa : first angiogenesis inhibitor approved for the treatment of advanced NSCLC.
Expert Rev Anticancer Ther; 2003 Jun; 3(3):257. PubMed ID: 12820770
[No Abstract] [Full Text] [Related]
17. Talactoferrin alpha receives fast-track designation for the treatment of non-small cell lung cancer.
McBride D
ONS Connect; 2007 Jan; 22(1):14. PubMed ID: 17393636
[No Abstract] [Full Text] [Related]
18. Cancer medicine hits a target.
Sobel RK
US News World Rep; 2002 Jun; 132(19):54. PubMed ID: 12066454
[No Abstract] [Full Text] [Related]
19. Gefitinib in patients with non-small cell lung cancer: symptomatic improvement within a few days.
Bearz A; Vaccher E; Spazzapan S; Berretta M; Tirelli U
Lung Cancer; 2005 Sep; 49(3):417-8. PubMed ID: 16102608
[No Abstract] [Full Text] [Related]
20. Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer.
Viswanathan A; Pillot G; Govindan R
Lung Cancer; 2005 Dec; 50(3):417-8. PubMed ID: 16129510
[No Abstract] [Full Text] [Related]
[Next] [New Search]
